Amgen's erenumab recently secured FDA approval as the first G protein-coupled receptor-targeted antibody. More of these biologics are on the way, despite remaining challenges.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Amino terminal recognition by a CCR6 chemokine receptor antibody blocks CCL20 signaling and IL-17 expression via β-arrestin
BMC Biotechnology Open Access 05 July 2021
-
G protein-coupled receptors: structure- and function-based drug discovery
Signal Transduction and Targeted Therapy Open Access 08 January 2021
-
Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors
Communications Biology Open Access 26 March 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Dolgin, E. First GPCR-directed antibody passes approval milestone. Nat Rev Drug Discov 17, 457–459 (2018). https://doi.org/10.1038/nrd.2018.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.103
This article is cited by
-
Amino terminal recognition by a CCR6 chemokine receptor antibody blocks CCL20 signaling and IL-17 expression via β-arrestin
BMC Biotechnology (2021)
-
G protein-coupled receptors: structure- and function-based drug discovery
Signal Transduction and Targeted Therapy (2021)
-
Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors
Communications Biology (2020)